Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Cetuximab + Encorafenib + ERAS-007 |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | predicted - sensitive | Cetuximab + Encorafenib + ERAS-007 | Case Reports/Case Series | Actionable | In a Phase Ib/II trial (HERKULES), combination treatment with ERAS-007, Erbitux (cetuximab), and Braftovi (encorafenib) demonstrated safety and activity in patients with metastatic colorectal cancer harboring BRAF V600E, resulting in 1 confirmed and 1 unconfirmed partial response of 4 efficacy evaluable patients (J Clin Oncol 41, 2023 (suppl 16; abstr 3557); NCT05039177). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). | Full reference... |